Australia's medical cannabis market is one of the most accessible and fastest-growing import channels for Canadian Licensed Producers. Under the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC), qualified importers can bring Health Canada-licensed dried flower into the Australian medical supply chain. The permit framework is structured, the compliance bar is high, and the premium flower segment rewards suppliers who can consistently deliver product that meets TGO 93.
For a Canadian LP with export authorisation under the Cannabis Act, the Australian channel is a realistic near-term opportunity. Getting there requires aligning your Health Canada export permit process with Australia's ODC narcotic import permit, satisfying TGO 93 quality standards, and understanding when the TGA Special Access Scheme applies to your buyer's patients. This guide covers the full end-to-end picture.
How Australia's Medical Cannabis Import Framework Works
Australia regulates cannabis imports through two parallel systems. The ODC, sitting within the Department of Home Affairs, controls the narcotic permit layer, mirroring Australia's obligations under the Single Convention on Narcotic Drugs (1961). The TGA regulates the therapeutic goods side: quality, safety, and sponsor licensing.
Your Australian buyer needs two things before your product can land: an ODC narcotic import permit for the shipment, and a TGA licence to import and supply a Schedule 8 substance. On the Canadian side, you need an export permit from Health Canada and, for dried flower, a phytosanitary certificate issued by the Canadian Food Inspection Agency (CFIA). Both sides of the permit chain must be aligned before the shipment moves.
Australia does not require EU-GMP certification to import Canadian cannabis, but your product must comply with TGO 93, the Therapeutic Goods Order that governs the quality of medicinal cannabis products in Australia. TGO 93 sets requirements for cannabinoid potency, pesticide residues, heavy metals, microbial limits, and moisture content. Your COA from an ISO/IEC 17025-accredited laboratory is the primary document your buyer uses to confirm TGO 93 compliance.
TGO 93 Compliance: What It Actually Requires
TGO 93 is Australia's quality standard for medicinal cannabis products. For imported dried flower, the most material requirements are cannabinoid potency limits, microbial contamination thresholds, pesticide residue limits, and heavy metal limits. Your batch COA needs to address all of these. If your testing laboratory is ISO/IEC 17025-accredited, that accreditation satisfies the testing methodology requirements that TGO 93 implies.
A few specifics worth understanding before you quote an Australian buyer:
- Total THC calculation: Australia uses a specific formula that accounts for decarboxylation. Your COA should report both THCA and delta-9 THC so total THC can be computed correctly.
- Pesticide residues: TGO 93 references the TGA's list of permitted pesticide residues. Health Canada's permitted residues do not map 1:1 to Australia's list. Review the TGA pesticide schedule against your cultivation inputs before assuming your COA passes.
- Moisture content: The TGO 93 specification for dried cannabis sets a moisture content limit. Confirm your batch falls within spec, especially for long-haul shipments where moisture can shift during transit.
When preparing your COA for an Australian buyer, verify that your lab reports in the format and units TGO 93 expects. See our guide on how to read a cannabis certificate of analysis for the key fields a B2B buyer will check. A COA that doesn't clearly address TGO 93 parameters will slow the buyer's TGA submission, which delays your payment.
The TGA Special Access Scheme and What It Means for Your Buyer
Australia operates a tiered access system for medicinal cannabis products that aren't on the Australian Register of Therapeutic Goods (ARTG). The two routes that matter for your buyer are the TGA Special Access Scheme B (SAS-B), where a medical practitioner applies for access for an individual patient, and the Authorised Prescriber scheme, where a physician is approved to prescribe a specific product to multiple patients without individual applications.
As a Canadian LP, your product almost certainly enters through one of these routes unless your buyer has registered a finished product on the ARTG (rare for imported dried flower). SAS-B and Authorised Prescriber volumes can scale meaningfully: many Australian importers are supplying thousands of patients across both pathways. The practical implication for you is that your buyer will want batch-level COA access quickly, because TGA submissions sometimes require COA data before prescriptions can proceed. Build your document delivery process around this.
The Export Permit Process on the Canadian Side
Under the Cannabis Act, a Licensed Producer must hold export authorisation as part of its Health Canada licence to export cannabis to any country. If your licence does not currently include export authorisation, you'll need to apply for an amendment before you can move forward. Health Canada's export permit application requires details of the shipment (quantity, product form, batch numbers), the importer's ODC permit number, and the destination country's import permit.
The timing sequence matters. Your Australian buyer obtains their ODC narcotic import permit first, because that permit number must appear on your Health Canada export permit application. Once both permits are in hand, the shipment can be arranged. Health Canada typically processes export permits within a few weeks, but permit validity windows and permit-linked batch numbers mean you need to coordinate closely with your buyer so the permits don't expire before the shipment moves.
You'll also need the CFIA phytosanitary certificate. Australia's biosecurity requirements for plant material are enforced by the Australian Department of Agriculture, Fisheries and Forestry, and cannabis dried flower is subject to import conditions. Your CFIA inspector will need access to the batch and supporting documentation before issuing the certificate. Build this into your pre-shipment timeline.
Practical Steps for a First Shipment to Australia
- Confirm your licence includes export authorisation. If not, submit the amendment to Health Canada before engaging any Australian buyer commercially.
- Qualify a buyer with TGA importer status. Your buyer must hold a TGA licence to import Schedule 8 substances. Ask for their licence number before advancing discussions. An unlicensed buyer cannot receive your shipment legally.
- Send your COA and product specification early. Your buyer needs TGO 93-mapped COA data to run their TGA submission. Delays here are the most common source of shipment holdups. If you can provide pre-batch or similar-lot COA data during the commercial discussion, do it.
- Obtain an ODC narcotic import permit from your buyer. Your buyer applies to the ODC. Once they receive the permit, send it to your Health Canada export permit application. This is the sequencing constraint most first-time exporters get wrong.
- Apply to Health Canada for the export permit. Reference the ODC permit number, batch details, and consignee. Health Canada will issue a permit tied to specific batch quantities.
- Arrange the CFIA phytosanitary certificate. Book the CFIA inspection in parallel with your export permit application. The certificate must accompany the shipment.
- Arrange freight with a licensed narcotic forwarder. Not all freight forwarders are licensed to handle Schedule 8 narcotics in Australia. Confirm your forwarder's credentials on both ends before booking.
- Prepare the shipment documentation package. At a minimum: export permit, phytosanitary certificate, COA, commercial invoice, packing list, and ODC permit copy. Your buyer's customs broker will tell you if additional documents are required.
How AlphaLeaf Approaches Australian Market Supply
AlphaLeaf holds export authorisation under its Health Canada Standard Cultivation licence and produces hand-trimmed dried flower from its Montreal indoor facility. Every batch ships with a full COA from an ISO/IEC 17025-accredited laboratory, covering cannabinoid potency, terpene panel, pesticide residues, heavy metals, and microbials. The batch traceability system means we can generate lot-specific documentation quickly, which matters when your buyer is running a time-sensitive TGA submission.
Our Ice Cream Cake cultivar (30.3% Total THC, Wedding Cake x Gelato cross, large-bud format) is well-suited to the Australian premium flower segment, where consistent potency and terpene expression drive repeat orders. If you're a TGA-licensed importer looking for a Canadian supply partner, reach out to our international team to discuss your programme requirements.
For more on our export capabilities and certifications, or to review our product range and batch data, we're happy to provide documentation packages on request.
Frequently Asked Questions
Does Australia require EU-GMP certification to import Canadian cannabis?
No. Australia does not require EU-GMP certification for imported medicinal cannabis. The relevant quality standard is TGO 93, which sets requirements for cannabinoid potency, microbial limits, pesticide residues, and heavy metals. A COA from an ISO/IEC 17025-accredited laboratory is the standard document used to demonstrate TGO 93 compliance.
What is the ODC narcotic import permit and who applies for it?
The ODC narcotic import permit is issued by Australia's Office of Drug Control to licensed importers in Australia. The Australian buyer (your customer) applies for this permit, not the Canadian exporter. The permit number must be included in the Canadian LP's Health Canada export permit application. This means the Australian buyer must have their ODC permit in hand before the Canadian LP can complete its export permit application.
Does a Canadian LP need to do anything specific to export to Australia vs Germany?
The Canadian side is similar: export authorisation under the Cannabis Act, a Health Canada export permit for each shipment, and a CFIA phytosanitary certificate. The destination-side requirements differ significantly. Germany requires EU-GMP certification and a BfArM narcotic import permit. Australia requires TGO 93-compliant product documentation and an ODC narcotic import permit. Australia does not require EU-GMP, which can make it a more accessible first export market for LPs that are not yet EU-GMP certified.
What does a TGA-licensed importer need from the Canadian LP before they can submit to TGA?
The Australian importer typically needs: a batch COA from an ISO/IEC 17025-accredited laboratory covering TGO 93 parameters, a product specification document, the Canadian LP's Health Canada licence details (including export authorisation), and in some cases a certificate of pharmaceutical product or equivalent Good Manufacturing Practice documentation. The exact requirements vary depending on whether the importer is using the SAS-B, Authorised Prescriber, or ARTG pathway.
How long does the full permit process take for a first shipment to Australia?
Plan for a minimum of 8 to 12 weeks from first commercial agreement to shipment for a first-time export. The main variables are: the ODC permit processing time on the Australian side (typically 4 to 6 weeks), Health Canada export permit processing time (2 to 4 weeks), and CFIA inspection scheduling. The ODC permit is the critical path item because it gates the Health Canada application. Experienced importers with repeat permit histories can move faster on their end.
